{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:46:03Z","timestamp":1783122363800,"version":"3.54.6"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["107595\/Z\/15\/Z"],"award-info":[{"award-number":["107595\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI129910"],"award-info":[{"award-number":["U19AI129910"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Control of cutaneous leishmaniasis (CL) relies on chemotherapy, yet gaps in our understanding of the determinants of therapeutic outcome impede optimization of antileishmanial drug regimens. Pharmacodynamic (PD) parameters of antimicrobials are based on the relationship between drug concentrations\/exposure and microbial kill. However, viable Leishmania persist in a high proportion of individuals despite clinical resolution, indicating that determinants other than parasite clearance are involved in drug efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, the profiles of expression of neutrophils, monocytes, Th1 and Th17 gene signatures were characterized in peripheral blood mononuclear cells (PBMCs) during treatment with meglumine antimoniate (MA) and clinical cure of human CL caused by Leishmania (Viannia). We explored relationships of immune gene expression with plasma and intracellular antimony (Sb) concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our findings show a rapid and orchestrated modulation of gene expression networks upon exposure to MA. We report nonlinear pharmacokinetic\/pharmacodynamic (PK\/PD) relationships of Sb and gene expression dynamics in PBMCs , concurring with a time lag in the detection of intracellular drug concentrations and with PK evidence of intracellular Sb accumulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results quantitatively portray the immune dynamics of therapeutic healing, and provide the knowledge base for optimization of antimonial drug treatments, guiding the selection and\/or design of targeted drug delivery systems and strategies for targeted immunomodulation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa1206","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T19:26:20Z","timestamp":1597346780000},"page":"e484-e492","source":"Crossref","is-referenced-by-count":8,"title":["Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by<i>Leishmania<\/i>(<i>Viannia<\/i>)"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-1563","authenticated-orcid":false,"given":"Mar\u00eda Adelaida","family":"G\u00f3mez","sequence":"first","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Navas","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Dario","family":"Prieto","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Giraldo-Parra","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cossio","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Alexander","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Gore Saravia","sequence":"additional","affiliation":[{"name":"Centro Internacional de Entrenamiento e Investigaciones M\u00e9dicas-CIDEIM, Cali, Colombia"},{"name":"Universidad Icesi, Cali, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2021051810404938700_CIT0001","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1086\/503371","article-title":"Resistance to antimony and treatment failure in human Leishmania (Viannia) infection","volume":"193","author":"Rojas","year":"2006","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0002","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4269\/ajtmh.13-0096","article-title":"In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis","volume":"89","author":"Prajapati","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2021051810404938700_CIT0003","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/AAC.01023-13","article-title":"Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species","volume":"58","author":"Obonaga","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051810404938700_CIT0004","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1128\/IAI.68.1.288-293.2000","article-title":"Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis","volume":"68","author":"Murray","year":"2000","journal-title":"Infect Immun"},{"key":"2021051810404938700_CIT0005","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1128\/IAI.68.11.6289-6293.2000","article-title":"Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment","volume":"68","author":"Murray","year":"2000","journal-title":"Infect Immun"},{"key":"2021051810404938700_CIT0006","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1086\/315890","article-title":"Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis","volume":"182","author":"Murray","year":"2000","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","article-title":"Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species","volume":"64","author":"Palacios","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"2021051810404938700_CIT0008","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4269\/ajtmh.2005.72.421","article-title":"Short report: efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis","volume":"72","author":"Soto","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2021051810404938700_CIT0009","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"V\u00e9lez","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2021051810404938700_CIT0010","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1086\/510860","article-title":"Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate","volume":"195","author":"Cruz","year":"2007","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0012","doi-asserted-by":"crossref","first-page":"e02198","DOI":"10.1128\/AAC.02198-16","article-title":"Pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis","volume":"61","author":"Castro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051810404938700_CIT0013","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/jac\/dky143","article-title":"Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure-response relationships","volume":"73","author":"Kip","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021051810404938700_CIT0014","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"Scott","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2021051810404938700_CIT0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/505583","article-title":"Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment","volume":"194","author":"Vergel","year":"2006","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0016","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1086\/515355","article-title":"Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients","volume":"178","author":"Schubach","year":"1998","journal-title":"J Infect Dis"},{"key":"2021051810404938700_CIT0017","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4269\/ajtmh.1998.58.824","article-title":"Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure","volume":"58","author":"Schubach","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2021051810404938700_CIT0018","volume-title":"Leishmaniasis in the Americas: treatment recommendations","author":"Organization PAH","year":"2013"},{"key":"2021051810404938700_CIT0019","doi-asserted-by":"crossref","first-page":"e2130","DOI":"10.1371\/journal.pntd.0002130","article-title":"Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis","volume":"7","author":"Olliaro","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2021051810404938700_CIT0020","author":"R_Core_Tea"},{"key":"2021051810404938700_CIT0021","first-page":"11","article-title":"Simple, automatic noncompartmental analysis: the PKNCA R package","volume":"42","author":"Denney","year":"2015","journal-title":"J Pharmacokinet Phar"},{"key":"2021051810404938700_CIT0022","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1128\/IAI.00764-19","article-title":"Profiles of local and systemic inflammation in the outcome of treatment of human cutaneous leishmaniasis caused by Leishmania (Viannia)","volume":"88","author":"Navas","year":"2020","journal-title":"Infect Immun"},{"key":"2021051810404938700_CIT0023","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1371\/journal.pcbi.0030206","article-title":"Construction, visualisation, and clustering of transcription networks from microarray expression data","volume":"3","author":"Freeman","year":"2007","journal-title":"PLoS Comput Biol"},{"key":"2021051810404938700_CIT0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-61779-361-5_15","article-title":"Using MCL to extract clusters from networks","volume":"804","author":"van Dongen","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2021051810404938700_CIT0025","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1128\/IAI.01133-13","article-title":"Chronicity of dermal leishmaniasis caused by Leishmania panamensis is associated with parasite-mediated induction of chemokine gene expression","volume":"82","author":"Navas","year":"2014","journal-title":"Infect Immun"},{"key":"2021051810404938700_CIT0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18433\/J3GP53","article-title":"Understanding the hysteresis loop conundrum in pharmacokinetic\/pharmacodynamic relationships","volume":"17","author":"Louizos","year":"2014","journal-title":"J Pharm Pharm Sci"},{"key":"2021051810404938700_CIT0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"2021051810404938700_CIT0028","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jtbi.2008.10.025","article-title":"Exploring the role of the immune response in preventing antibiotic resistance","volume":"256","author":"Handel","year":"2009","journal-title":"J Theor Biol"},{"key":"2021051810404938700_CIT0029","doi-asserted-by":"crossref","first-page":"e1627","DOI":"10.1371\/journal.pntd.0001627","article-title":"Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species","volume":"6","author":"Rodriguez-Pinto","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2021051810404938700_CIT0030","first-page":"e00764","article-title":"Profiles of local and systemic inflammation in the outcome of treatment of human cutaneous leishmaniasis caused by L. Viannia","volume":"88","author":"Navas","year":"2019","journal-title":"Infect Immu"},{"key":"2021051810404938700_CIT0031","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1073\/pnas.1400352111","article-title":"Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections","volume":"111","author":"Ankomah","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021051810404938700_CIT0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug.\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2021051810404938700_CIT0033","doi-asserted-by":"crossref","first-page":"e02307","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051810404938700_CIT0034","doi-asserted-by":"crossref","first-page":"e0005713","DOI":"10.1371\/journal.pntd.0005713","article-title":"Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis","volume":"11","author":"Mart\u00ednez-Valencia","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2021051810404938700_CIT0035","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/AAC.39.2.516","article-title":"Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis","volume":"39","author":"al Jaser","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051810404938700_CIT0036","first-page":"393","article-title":"Metal transfer as a mechanism for metallothionein-mediated metal detoxification","volume":"46","author":"Roesijadi","year":"2000","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"2021051810404938700_CIT0037","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fphar.2019.00657","article-title":"Pharmacometabolomics of meglumine antimoniate in patients with cutaneous leishmaniasis","volume":"10","author":"Vargas","year":"2019","journal-title":"Front Pharmacol"},{"key":"2021051810404938700_CIT0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00204-009-0485-0","article-title":"Genotoxic effects of the antileishmanial drug Glucantime","volume":"84","author":"Lima","year":"2010","journal-title":"Arch Toxicol"},{"key":"2021051810404938700_CIT0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2019.12.022","article-title":"How the redox state regulates immunity","volume":"157","author":"Mullen","year":"2020","journal-title":"Free Radic Biol Med"},{"key":"2021051810404938700_CIT0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jac\/dkt334","article-title":"Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival","volume":"69","author":"G\u00f3mez","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021051810404938700_CIT0041","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1016\/S0021-9258(18)89027-5","article-title":"Distinct metal-binding configurations in metallothionein","volume":"260","author":"Nielson","year":"1985","journal-title":"J Biol Chem"},{"key":"2021051810404938700_CIT0042","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0006-2952(99)00301-9","article-title":"Regulation of metallothionein gene expression by oxidative stress and metal ions","volume":"59","author":"Andrews","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"2021051810404938700_CIT0043","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/03602539709037585","article-title":"Metallothionein in physiological and physiopathological processes","volume":"29","author":"Moffatt","year":"1997","journal-title":"Drug Metab Rev"},{"key":"2021051810404938700_CIT0044","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms14036044","article-title":"The role of metallothionein in oxidative stress","volume":"14","author":"Ruttkay-Nedecky","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2021051810404938700_CIT0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-nutr-080508-141119","article-title":"Functional significance of zinc-related signaling pathways in immune cells","volume":"29","author":"Haase","year":"2009","journal-title":"Annu Rev Nutr"},{"key":"2021051810404938700_CIT0046","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1023\/A:1018969429535","article-title":"Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study","volume":"10","author":"Gupta","year":"1993","journal-title":"Pharm Res"},{"key":"2021051810404938700_CIT0047","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/ni.1919","article-title":"Crucial role for human toll-like receptor 4 in the development of contact allergy to nickel","volume":"11","author":"Schmidt","year":"2010","journal-title":"Nat Immunol"},{"key":"2021051810404938700_CIT0048","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cod.12042","article-title":"Transition metal sensing by toll-like receptor-4: next to nickel, cobalt and palladium are potent human dendritic cell stimulators","volume":"68","author":"Rachmawati","year":"2013","journal-title":"Contact Dermatitis"},{"key":"2021051810404938700_CIT0049","doi-asserted-by":"crossref","first-page":"143720","DOI":"10.1155\/2015\/143720","article-title":"Metal-based nanoparticles and the immune system: activation, inflammation, and potential applications","volume":"2015","author":"Luo","year":"2015","journal-title":"Biomed Res Int"},{"key":"2021051810404938700_CIT0050","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1074\/jbc.M005423200","article-title":"Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani","volume":"276","author":"Shaked-Mishan","year":"2001","journal-title":"J Biol Chem"},{"key":"2021051810404938700_CIT0051","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/AAC.47.10.3073-3079.2003","article-title":"Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites","volume":"47","author":"Brochu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051810404938700_CIT0052","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1022823605068","article-title":"Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione","volume":"16","author":"Ferreira","year":"2003","journal-title":"Biometals"},{"key":"2021051810404938700_CIT0053","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1155\/S1565363303000153","article-title":"Resistance to arsenic- and antimony-based drugs","author":"Salerno","year":"2003","journal-title":"Bioinorg Chem Appl"},{"key":"2021051810404938700_CIT0054","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1517\/17425247.5.7.805","article-title":"Drug delivery systems against leishmaniasis? Still an open question","volume":"5","author":"Romero","year":"2008","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1206\/34944885\/ciaa1206.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/10\/e484\/37950762\/ciaa1206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/10\/e484\/37950762\/ciaa1206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T21:43:36Z","timestamp":1667771016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/10\/e484\/5895071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2021,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1206","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,15]]},"published":{"date-parts":[[2020,8,20]]}}}